
Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter. In Q4, Seres Therapeutics brought in $7.22 million in sales but lost $50.00 million in earnings.